Baidu
map

风湿免疫科

订阅

MedSci主页 / 所有栏目 / 风湿免疫科

Lentivector基因疗法治疗X连锁严重联合免疫缺陷

2019-06-12 不详 网络

X连锁严重联合免疫缺陷LentivectorNIAID
关注

SIRION公司近日宣布，美国国家过敏和传染病研究所（NIAID）将与SIRION签署许可协议，授权SIRION的LentiBOOST™技术，以提高Lentivector基因疗法治疗X连锁严重联合免疫缺陷的有效性。

SIRION公司近日宣布，美国国家过敏和传染病研究所（NIAID）将与SIRION签署许可协议，授权SIRION的LentiBOOST™技术，以提高Lentivector基因疗法治疗X连锁严重联合免疫缺陷的有效性。

X连锁严重联合免疫缺陷（SCID-X1）是由单个基因ILR2G突变引起的遗传性疾病。该突变导致T细胞、B细胞和自然杀伤（NK）细胞的严重损失，导致受影响儿童的免疫系统的严重损伤。出生时患有这种严重免疫缺陷的婴儿需要在婴儿期进行挽救生命的造血干细胞移植，但大多数患儿仅实现部分免疫重建。直到2016年，Lentivector基因疗法治疗以表达健康的ILR2G时，这一问题才得到逐步解决。


原始出处：

http://www.firstwordpharma.com/node/1646754#axzz5qOw0cfEI

本文系梅斯医学（MedSci）原创编译整理，转载需授权!

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1862780, encodeId=58361862e80ff, content=<a href='/topic/show?id=0b69542242' target=_blank style='color:#2F92EE;'>#CTO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5422, encryptionId=0b69542242, topicName=CTO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c66088, createdName=gao_jian4217, createdTime=Sat Apr 25 16:12:00 CST 2020, time=2020-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665430, encodeId=1b89166543032, content=<a href='/topic/show?id=f6fd1891e53' target=_blank style='color:#2F92EE;'>#X连锁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18917, encryptionId=f6fd1891e53, topicName=X连锁)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bdb025960146, createdName=12498ebem27暂无昵称, createdTime=Tue Apr 07 18:12:00 CST 2020, time=2020-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488990, encodeId=c5f8148899002, content=<a href='/topic/show?id=7df32913871' target=_blank style='color:#2F92EE;'>#免疫缺陷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29138, encryptionId=7df32913871, topicName=免疫缺陷)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=631b8488299, createdName=rebeccajiejie, createdTime=Fri Jun 14 08:12:00 CST 2019, time=2019-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=367659, encodeId=246236e65957, content=向挑战病魔的科研人员致敬！向挑战病魔的科研人员致敬, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5171668917, createdName=坚强007, createdTime=Wed Jun 12 21:05:21 CST 2019, time=2019-06-12, status=1, ipAttribution=)]
    2020-04-25 gao_jian4217

    #CTO#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1862780, encodeId=58361862e80ff, content=<a href='/topic/show?id=0b69542242' target=_blank style='color:#2F92EE;'>#CTO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5422, encryptionId=0b69542242, topicName=CTO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c66088, createdName=gao_jian4217, createdTime=Sat Apr 25 16:12:00 CST 2020, time=2020-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665430, encodeId=1b89166543032, content=<a href='/topic/show?id=f6fd1891e53' target=_blank style='color:#2F92EE;'>#X连锁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18917, encryptionId=f6fd1891e53, topicName=X连锁)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bdb025960146, createdName=12498ebem27暂无昵称, createdTime=Tue Apr 07 18:12:00 CST 2020, time=2020-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488990, encodeId=c5f8148899002, content=<a href='/topic/show?id=7df32913871' target=_blank style='color:#2F92EE;'>#免疫缺陷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29138, encryptionId=7df32913871, topicName=免疫缺陷)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=631b8488299, createdName=rebeccajiejie, createdTime=Fri Jun 14 08:12:00 CST 2019, time=2019-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=367659, encodeId=246236e65957, content=向挑战病魔的科研人员致敬！向挑战病魔的科研人员致敬, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5171668917, createdName=坚强007, createdTime=Wed Jun 12 21:05:21 CST 2019, time=2019-06-12, status=1, ipAttribution=)]
    2020-04-07 12498ebem27暂无昵称

    #X连锁#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1862780, encodeId=58361862e80ff, content=<a href='/topic/show?id=0b69542242' target=_blank style='color:#2F92EE;'>#CTO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5422, encryptionId=0b69542242, topicName=CTO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c66088, createdName=gao_jian4217, createdTime=Sat Apr 25 16:12:00 CST 2020, time=2020-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665430, encodeId=1b89166543032, content=<a href='/topic/show?id=f6fd1891e53' target=_blank style='color:#2F92EE;'>#X连锁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18917, encryptionId=f6fd1891e53, topicName=X连锁)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bdb025960146, createdName=12498ebem27暂无昵称, createdTime=Tue Apr 07 18:12:00 CST 2020, time=2020-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488990, encodeId=c5f8148899002, content=<a href='/topic/show?id=7df32913871' target=_blank style='color:#2F92EE;'>#免疫缺陷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29138, encryptionId=7df32913871, topicName=免疫缺陷)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=631b8488299, createdName=rebeccajiejie, createdTime=Fri Jun 14 08:12:00 CST 2019, time=2019-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=367659, encodeId=246236e65957, content=向挑战病魔的科研人员致敬！向挑战病魔的科研人员致敬, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5171668917, createdName=坚强007, createdTime=Wed Jun 12 21:05:21 CST 2019, time=2019-06-12, status=1, ipAttribution=)]
    2019-06-14 rebeccajiejie

    #免疫缺陷#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1862780, encodeId=58361862e80ff, content=<a href='/topic/show?id=0b69542242' target=_blank style='color:#2F92EE;'>#CTO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5422, encryptionId=0b69542242, topicName=CTO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c66088, createdName=gao_jian4217, createdTime=Sat Apr 25 16:12:00 CST 2020, time=2020-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665430, encodeId=1b89166543032, content=<a href='/topic/show?id=f6fd1891e53' target=_blank style='color:#2F92EE;'>#X连锁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18917, encryptionId=f6fd1891e53, topicName=X连锁)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bdb025960146, createdName=12498ebem27暂无昵称, createdTime=Tue Apr 07 18:12:00 CST 2020, time=2020-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488990, encodeId=c5f8148899002, content=<a href='/topic/show?id=7df32913871' target=_blank style='color:#2F92EE;'>#免疫缺陷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29138, encryptionId=7df32913871, topicName=免疫缺陷)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=631b8488299, createdName=rebeccajiejie, createdTime=Fri Jun 14 08:12:00 CST 2019, time=2019-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=367659, encodeId=246236e65957, content=向挑战病魔的科研人员致敬！向挑战病魔的科研人员致敬, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5171668917, createdName=坚强007, createdTime=Wed Jun 12 21:05:21 CST 2019, time=2019-06-12, status=1, ipAttribution=)]
    2019-06-12 坚强007

    向挑战病魔的科研人员致敬！向挑战病魔的科研人员致敬

    0

Baidu
map
Baidu
map
Baidu
map